---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-003421"
form_type: "8-K"
ticker: null
cik: "0000316253"
company_name: "ENZO BIOCHEM INC"
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:27:11.891400+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Enzo Biochem receives NYSE non-compliance notices for low market cap & stock price

## Summary
- NYSE notified Enzo of non-compliance due to 30-day avg market cap <$50M and equity <$50M (Oct 31, 2024).
- Additionally, average closing price of ENZ common stock was <$1.00 over consecutive 30 trading days.
- Company has 18 months to cure market cap/equity deficiency and 6 months to cure price deficiency.
- Enzo will notify NYSE by Jan 23, 2025 and submit a compliance plan by Feb 21, 2025.
- Common stock continues to trade on NYSE subject to other listing standards.

## SEC filing metadata
- accession: 0001213900-25-003421
- form_type: 8-K
- cik: 0000316253
- company_name: ENZO BIOCHEM INC
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/ea022765801-8k_enzobiochem.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-003421
- JSON: https://secwatch.observer/filing/0001213900-25-003421.json
- Plain text: https://secwatch.observer/filing/0001213900-25-003421.txt

## Source-grounded claims
- claim_id: 1c751a1b777842073f29d328770b16ccbc6dca3a
  claim: ENZO BIOCHEM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).
  evidence_excerpt: January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm
- claim_id: 8223b730a8264e58274e4a9f8880ad0a4f0e9336
  claim: ENZO BIOCHEM INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
  evidence_excerpt: January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.